Thela, Lindokuhle http://orcid.org/0000-0001-5483-2492
Decloedt, Eric
Zetterberg, Henrik
Gisslén, Magnus
Lesosky, Maia
Gleich, Melanie
Koutsilieri, Eleni
Scheller, Carsten
Hye, Abdul
Joska, John
Funding for this research was provided by:
Swedish Research Council (#2018-02532)
H2020 European Research Council (#681712, #101053962)
Swedish State Support for Clinical Research (#ALFGBG-71320)
Alzheimer Drug Discovery Foundation (#201809-2016862)
AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C)
Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (860197)
European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute at UCL (UKDRI-1003)
Swedish state under an agreement between the Swedish government and the county councils (ALFGBG-965885)
University of Cape Town
Article History
Received: 27 July 2022
Revised: 15 December 2022
Accepted: 21 January 2023
First Online: 15 February 2023
Declarations
:
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).